2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

Johnson & Johnson beat quarterly revenue and earnings expectations and slightly raised fiscal 2026 guidance, but its medtech business faces lower Impella demand and a U.S. Class 1 recall; a proposed $5.5 billion talc-lawsuit settlement remains a potential resolution. Amgen’s Q2 revenue grew 10% year over year to $10.1 billion, while Tavneos contributed $150 million (1.5% of sales) amid FDA pressure and denosumab sales fell with biosimilar competition. The article favors both as long-term dividend stocks, citing J&J’s 64-year payout-increase streak and Amgen’s 2.3% forward yield, while warning of near-term risks.

Analysis

Dividend durability and business durability are not the same trade. JNJ’s Impella issue is a concentrated product/adoption risk, but a Class 1 recall can have spillovers beyond direct sales: hospital procurement scrutiny and physician confidence may slow adoption even if subsequent trial data are favorable. Conversely, OTTAVA authorization is not yet commercial traction; the relevant proof points are procedure volume, surgeon adoption, and recurring instrument/service revenue versus established surgical-robotics platforms such as Intuitive Surgical.

AMGN’s more important pressure is the combination of biosimilar erosion and regulatory uncertainty, not Tavneos alone. Its relatively small current revenue contribution limits direct downside, while removal would also eliminate a growth contributor as older products face competition. MariTide is meaningful optionality, not yet an offset: efficacy, tolerability, persistence, dosing interval, and commercial differentiation versus Novo Nordisk and Eli Lilly remain to be demonstrated. Monthly dosing alone does not establish a durable advantage.

Over the next 1–3 months, monitor FDA action on Tavneos and JNJ’s Impella evidence/remediation; these can drive discrete sentiment moves. Over 6–18 months, JNJ’s surgical-robotics uptake and AMGN’s pipeline data matter more than dividend history. A broad-market drawdown could pressure both despite their income profiles; dividends are not crash protection. Without current valuation and catalyst dates, the article does not support an unconditional pair trade or a claim either stock is mispriced.

Key Decisions for Investors

• Keep JNJ on a staged-add watchlist rather than buying solely for its dividend. Consider adding only after Impella safety/remediation evidence is credible; thesis weakens if new safety concerns emerge or cardiovascular adoption remains impaired despite favorable data.
• Do not short AMGN simply on Tavneos risk: its direct sales exposure is limited, while the larger underwriting question is whether pipeline growth offsets denosumab biosimilar erosion. Reassess on FDA action and product-level growth/guidance; a deteriorating growth outlook would falsify the resilience case.
• Treat MariTide as unpriced-to-be-verified optionality, not a present earnings substitute. Require clinical data on efficacy, tolerability, durability, and dosing plus evidence of differentiation from Novo Nordisk and Eli Lilly before increasing exposure on the obesity thesis.
• No broad-market crash hedge is implied by either dividend record. Before initiating a relative JNJ/AMGN position, check valuation, relative performance, and upcoming catalyst dates; avoid forcing a pair trade where those inputs are unavailable.